|
Webcast to discuss, XDEMVY approved for the treatment of Demodex blepharitis
 Bobby Azamian CEO Tarsus Bobby cofounded Tarsus Pharmaceuticals, Inc. with Michael Ackermann in November 2016 and has served as its President and CEO since September 2018. He has served as the company’s Chairman since December 2022. Since its founding, Tarsus has established a leading team and culture and has completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline, including its lead investigational therapy, TP-03.
Bobby cofounded and led 2 other novel therapeutics companies, Vibrato Medical, focused on wearable treatments for peripheral arterial diseases, and Metavention, focused on interventional treatments for metabolic diseases. Bobby currently serves on the Board of Vibrato Medical and previously held the role as Board Co-Chair, leading the company through Series A financing and securing numerous significant NIH grant awards. Bobby served as President and CMO of Metavention, leading the company through multiple clinical trial programs and Series A through C financings.
Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer for numerous life sciences companies. He also served on the board of the nonprofit organization Octane.
Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received his MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. Bobby enjoys sports, travel, and the arts and spending time in Newport Beach with his wife, dog, and extended family.
 Aziz Mottiwala Chief Commercial Officer Tarsus Aziz has over 20 years of biopharmaceutical industry leadership experience in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s addiction medicine portfolio. Before that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan (an AbbVie company), most recently as Vice President of Marketing for the company’s eye care franchise, where he helped grow the business to over $2 billion in revenue across a diverse portfolio including Restasis® and Lumigan®, as well as several other devices and OTC product lines.
Previously, Aziz held commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a BS in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the boards of the Orange County nonprofit OneOC and Octane.
 David Nakasone Head of Investor Relations Tarsus
|
|
|
|